KOSDAQBiotech & Pharma187420

HLB Genex

₩1,681▼ 2.04%2026-11-18 close
Market Cap
₩54.9B
Turnover
₩200M
Volume
110K
Shares out.
32.7M
PER
7.0×
PBR
1.2×
EPS
₩274
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Enzyme Business Stays Profitable, Quarterly Results Mixed

HLB Genex turned operating profit positive in 2025 on industrial enzyme sales growth and has kept quarterly operating profit positive through Q3 2026, while net income attributable to controlling shareholders has swung between profit and loss from quarter to quarter.

  1. 1

    Revenue in 2025 was KRW 43.4 billion, up 22.4% year on year, and operating profit of KRW 1.21 billion marked a turn to profit.

  2. 2

    Q3 2026 revenue was KRW 11.7 billion, up 15.3% year on year, and operating profit of KRW 1.42 billion swung to profit from a year earlier.

  3. 3

    Net income attributable to controlling shareholders totals KRW 7.9 billion over the last four quarters, yet Q3 2026 returned to a net loss of KRW 5.18 billion.

  4. 4

    The debt-to-equity ratio fell to 148.1% at end-2025 from 418.3% in 2024, and operating cash flow was positive in both 2024 and 2025.

  5. 5

    The company said it expanded semiconductor-grade catalase capacity to 2,616,000 kg combined across its two plants in China.

02

Business structure

HLB Genex develops and produces specialty industrial enzymes and bio-based healthcare materials, and industrial enzymes are its core business.

Its main products are semiconductor-grade catalase, which removes residual hydrogen peroxide in chip cleaning and water treatment processes, and food-grade lactase, which breaks down lactose. Catalase sales grew mainly from customers in Korea and Taiwan, while lactase supply has been broadened across more buyers.

UDCAse, an enzyme used in making ursodeoxycholic acid (UDCA), began reflecting in sales from Q2 2024 and started contributing meaningfully in Q1 2026. Protease NT, an enzyme for collagen tripeptide production, more than doubled its sales in Q1 2026 from a year earlier.

On a standalone basis for H1 2026, the health functional food segment grew more than 40% from the prior-year half, and fiber-use catalase posted growth in the 60% range in Q2.

A Korean IR research firm said in a February 2026 report that fermentation-based vitamin K2 (MK-7) and a cosmetic ingredient, phytosphingosine, are moving toward commercialization.

HLB Genex is an affiliate of the HLB group and has been central to the group's restructuring through acquisitions of drug-development affiliates. A subsidiary's revenue was reported to have risen 26% year on year in Q1 2026. The largest shareholder, HLB, and ten related parties reported a combined stake of 40.93% as of May 26, 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩10.2B-₩400M−3.8%
2025Q4₩12.5B-₩700M−5.2%
2026Q1₩11.7B₩1B8.6%
2026Q2₩11.3B₩1B8.7%
2026Q3₩11.7B₩1.4B12.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩27.8B-₩6.2B-₩13B−22.4%−54.3%394.6%
2023₩27B-₩9.5B-₩3B−35.0%−13.4%271.2%
2024₩35.4B-₩1.9B-₩18.8B−5.3%−79.2%418.3%
2025₩43.4B₩1.2B₩22.6B2.8%55.2%148.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

In the annual results on record, revenue fell from KRW 27.8 billion in 2022 to KRW 27 billion in 2023 (down 2.9% year on year), then rose to KRW 35.4 billion in 2024 (up 31.2%) and KRW 43.4 billion in 2025 (up 22.4%), growing in two consecutive years. Of the 2022 to 2025 period, 2025 was the largest year.

The company attributed the 2025 gain to steady sales of catalase and lactase, new product launches, and expanded overseas exports. Operating losses of KRW 6.22 billion in 2022 and KRW 9.46 billion in 2023 widened the deficit, before narrowing to KRW 1.88 billion in 2024.

In 2025, operating profit of KRW 1.21 billion marked a turn to profit, with an operating margin of 2.8%. Net income attributable to controlling shareholders was a loss of KRW 18.8 billion in 2024 and a profit of KRW 22.6 billion in 2025.

Net income including non-controlling interests was KRW 22.9 billion in 2025, a different figure from the controlling-shareholder measure. The gap between operating profit and net profit suggests non-operating items had a large effect.

At end-2025, total equity was KRW 54.7 billion, of which KRW 40.9 billion belonged to controlling shareholders, and total liabilities were KRW 81.1 billion. Quarterly results in 2026 have been mixed.

Q4 2025 revenue was KRW 12.5 billion, up 22.6% from the prior quarter, and controlling-shareholder net income was KRW 9.06 billion, but operating loss widened to KRW 655 million. Q1 2026 posted revenue of KRW 11.7 billion and operating profit of KRW 1 billion, but a controlling-shareholder net loss of KRW 2.47 billion.

Q2 2026 revenue was KRW 11.3 billion with operating profit of KRW 983 million and net income of KRW 6.5 billion. Q3 2026 revenue was KRW 11.7 billion with operating profit of KRW 1.42 billion, but a controlling-shareholder net loss of KRW 5.18 billion widened.

05

Industry analysis

Catalase removes residual hydrogen peroxide in chip cleaning and water treatment processes in an environmentally friendly way, and is described as a product that meets both process stability and environmental regulation requirements.

A March 2026 news report attributed catalase sales growth to an improving semiconductor cycle and rising deliveries to Korean chipmakers. Analysts also said demand could persist alongside the semiconductor supercycle. Still, if the chip cycle turns down, catalase orders could weaken with it.

Lactase is used in premium infant formula and functional food ingredients, and supply to global customers has grown alongside the expansion of the prebiotic GOS market. The company is pursuing a strategy of securing multiple demand sources across food and semiconductors to reduce reliance on any one industry.

Unlike many listed biopharma companies whose revenue centers on drug pipelines, HLB Genex's profit base is enzyme materials, so its business structure differs. Competitiveness rests on how deeply its core enzymes are embedded in customer processes and on production capacity.

The catalase capacity expansion reported in 2026 adds room to respond to rising demand. Drug development capabilities sit mainly in group affiliates, so comparisons within the pharma sector should first account for the difference in business models.

06

Outlook

The company said it plans to keep strengthening its core enzyme business and improving operating efficiency to sustain growth in Q4 2026. Catalase capacity has been expanded to 2,616,000 kg combined across two plants in China.

UDCAse, an ingredient for liver-function improvement drugs, has new products planned, and expanding overseas exports of the antioxidant enzyme SOD was presented as a strategic task.

A Korean IR research firm forecast 2026 consolidated revenue of KRW 49.5 billion and operating profit of KRW 2.6 billion in a February 2026 report. Reported cumulative operating profit through Q3 2026 was KRW 3.4 billion, meaning a large part of that forecast is already reflected.

The same report saw expanding semiconductor processes and premium food growth as raising earnings visibility. However, quarterly swings in net income have not disappeared, and periods in which operating profit and net income point in different directions continue.

The next checkpoint is the annual profit figures confirmed in the 2026 annual report and the full-year tally of Q4 2026 operating profit. On the group pipeline side, a 2025 report presented filing a clinical trial plan for NT-3 in 2027 as a plan of the HLB group affiliate developing it.

07

Valuation

PER
7.0×
PBR
1.2×
ROE
18.5%
EPS
₩274
BPS
₩1,547
Dividend per share
₩0

The price-to-book ratio is above 1x, which means the stock trades at a premium to net assets. Controlling-shareholder equity was KRW 40.9 billion at end-2025 and total equity was KRW 54.7 billion, so the gap between market price and book value is the key comparison.

On earnings, net income attributable to controlling shareholders totals KRW 7.9 billion over the last four quarters, and because quarterly results alternate between profit and loss, earnings multiples change considerably depending on the period chosen. Dividend income is effectively negligible at present.

With 2025 operating profit at KRW 1.21 billion, the scale is small, so non-operating items have a relatively large effect. Q3 2026 operating profit of KRW 1.42 billion turned to profit year on year, but the controlling-shareholder net loss widened to KRW 5.18 billion. A balanced reading of valuation should consider earnings-based and asset-based measures together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Operating profit has stayed positive

After turning to profit in 2025, quarterly operating profit stayed positive, at KRW 1 billion in Q1 2026, KRW 983 million in Q2, and KRW 1.42 billion in Q3. Catalase and lactase have kept the revenue base steady while UDCAse is establishing itself as a new revenue source.

Capacity and portfolio diversification

Catalase capacity was expanded to 2,616,000 kg combined across two plants in China.

Fiber-use catalase grew in the 60% range in Q2 2026 on a single-quarter basis, and the health functional food segment grew more than 40% in H1 2026 on a standalone basis, showing up in the numbers as a lower dependence on any one industry.

Improved financial structure

The debt-to-equity ratio fell from 418.3% in 2024 to 148.1% in 2025. Operating cash flow was positive for two consecutive years, at KRW 2.87 billion in 2024 and KRW 3.5 billion in 2025. In August 2026, the company bought back KRW 19.6 billion of convertible bonds before maturity.

09

Bear factors

Volatile quarterly net income

Operating profit stayed positive, but net income attributable to controlling shareholders changed direction each quarter. It went from a KRW 2.47 billion loss in Q1 2026 to KRW 6.5 billion profit in Q2 and a KRW 5.18 billion loss in Q3. Operating profit and net income continuing to point in different directions is the main bearish point.

Thin operating profit base

Operating profit in 2025 was KRW 1.21 billion, with an operating margin of 2.8%, leaving a thin cushion. On revenue of KRW 43.4 billion, the small profit base could be sensitive to cost or pricing changes.

The swing from a KRW 1.88 billion operating loss in 2024 to profit was real, but the profit margin itself is small.

Dependence on the largest shareholder and group structure

The largest shareholder, HLB, together with ten related parties, held 40.93% as of May 26, 2026. As the group restructured its governance through acquisitions of drug-development affiliates, HLB Genex's financing capacity is tied to group strategy.

The more the parent supports the company, the more its independent business decisions and intra-group terms need to be examined.

10

Risk factors

Concentrated industrial demand

Catalase serves semiconductor processes and lactase serves food ingredients, so core revenue depends on demand from two industries. If the chip cycle slows, orders from customers in Korea and Taiwan could decline. Food volumes can also shift with global customers' supply arrangements. The key question is how far new product sales can offset these swings.

Group and governance risk

The largest shareholder and related parties hold 40.93%, and the group has continued intra-group stake purchases and acquisitions. A 2025 report noted the possibility of raising outside funds through HLB Genex as a listed parent-affiliate.

When group funding flows overlap with the company's financial decisions, market views on business independence can shift.

Financial cushion and earnings durability

Total liabilities at end-2025 were KRW 81.1 billion against total equity of KRW 54.7 billion. The debt-to-equity ratio fell from 418.3% in 2024 but liabilities still exceed equity. With controlling-shareholder net income moving between profit and loss, how durable the profit structure is will matter.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    The starting point for checking whether Q4 2026 operating profit and controlling-shareholder net income move in the same direction as the trend through Q3.

  2. Late March 2027 (around the 2026 annual report filing deadline)

    The 2026 annual report will confirm full-year revenue, operating margin and net income attributable to controlling shareholders, showing how the 2026 quarters add up on an annual basis.

  3. Mid-May 2027 (Q1 2026 results were disclosed on May 14, 2026)

    Whether Q1 2027 revenue and operating profit hold near the KRW 11.7 billion and KRW 1 billion of Q1 2026, and whether new products such as UDCAse keep growing.

  4. During 2027 (plan as reported in May 2025)

    A May 2025 report presented a 2027 clinical trial plan filing for NT-3 at a group affiliate as a plan. Progress should be rechecked against the latest disclosures.

12

Overall view

HLB Genex turned operating profit positive in 2025 on industrial enzyme sales growth, and quarterly operating profit stayed positive through Q1 to Q3 2026. Annual revenue grew in two consecutive years through 2024 and 2025, and the debt-to-equity ratio fell from 418.3% in 2024 to 148.1% in 2025.

However, net income attributable to controlling shareholders alternated between profit and loss across 2026 quarters, and the Q3 loss of KRW 5.18 billion widened. Bullish factors include sustained operating profit, expanded capacity, and portfolio growth in new products and health functional foods.

Bearish factors include net income volatility, a thin operating profit base, and dependence on the largest shareholder and group structure. How valuation is read depends on whether earnings-based or net-asset-based measures are used. The next checkpoints are the full-year figures confirmed in the 2026 annual report and Q1 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. etoday.co.kr
  2. enewstoday.co.kr
  3. m.news.nate.com
  4. m.news.nate.com
  5. supple.kr
  6. newspim.com
  7. news.nate.com
  8. m.news.nate.com
  9. news.nate.com
  10. m.thebell.co.kr
  11. news.nate.com
  12. supple.kr
  13. lawissue.co.kr
  14. digitaltoday.co.kr
  15. view.asiae.co.kr
  16. job-post.co.kr
  17. medifonews.com
  18. press9.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis